baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Fate Therapeutics Inc/ US31189P1021 /

14/06/2024 16:28:07	Chg. -0.0550	Volume	Bid16:28:24	Ask16:28:24	High	Low
3.7050USD	-1.46%	818,624 Turnover: 2.9 mill.	3.7000Bid Size: 300	3.7100Ask Size: 400	3.7700	3.6125

GlobeNewswire 04/06 Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 29/05 Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

GlobeNewswire 09/05 Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

GlobeNewswire 09/05 Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-she...

GlobeNewswire 06/05 Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Oper...

GlobeNewswire 03/05 Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-b...

GlobeNewswire 22/04 Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmu...

GlobeNewswire 03/04 Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire 02/04 Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 02/04 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

GlobeNewswire 19/03 Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Pla...

GlobeNewswire 05/03 Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01/03 Fate Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire 26/02 Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire 15/02 Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial R...

Newsfile Corp 15/02 Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

GlobeNewswire 02/02 Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 08/01 Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients wi...

GlobeNewswire 13/12/2023 Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 08/11/2023 Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire 04/11/2023 FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Beh...

GlobeNewswire 02/11/2023 SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encour...

GlobeNewswire 25/10/2023 Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

GlobeNewswire 10/09/2023 Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, In...

GlobeNewswire 31/08/2023 Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics Inc/ US31189P1021 /

If you wish to receive reply to your feedback, please provide your email address.